Operations: Currently, there are no reported revenue segments for the company.

Market Cap: A$14.95M

Lode Resources Ltd, with a market cap of A$14.95 million, is pre-revenue and remains unprofitable with losses increasing at 20.1% annually over the past five years. The company has no debt, and its short-term assets (A$2.3 million) exceed both short- and long-term liabilities, indicating some financial stability despite less than a year of cash runway if cash flow trends persist. Recent earnings show a net loss of A$1.17 million for the year ended June 2024, slightly higher than the previous year's loss of A$1.12 million, reflecting ongoing challenges in achieving profitability amidst high share price volatility.

• Click here and access our complete financial health analysis report to understand the dynamics of Lode Resources.

• Evaluate Lode Resources' historical performance by accessing our past performance report.

Proteomics International Laboratories

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Proteomics International Laboratories Ltd is a medical technology company specializing in proteomics across several regions including Australia, New Zealand, the United States, Europe, India, and South East Asia with a market cap of A$100.22 million.

Operations: The company generates A$3.28 million in revenue from its operational activities.

Market Cap: A$100.22M

Proteomics International Laboratories Ltd, with a market cap of A$100.22 million, is currently unprofitable, reporting a net loss of A$6.38 million for the fiscal year ending June 2024. Despite generating A$3.28 million in revenue, it lacks meaningful revenue streams typical of penny stocks in the biotech sector. The company has no debt and its short-term assets significantly cover both short- and long-term liabilities, indicating a stable financial position despite less than a year of cash runway if cash flow continues to decline at historical rates. Recent board changes include appointing James Williams as an independent non-executive director, potentially strengthening strategic oversight given his extensive industry experience.

• Jump into the full analysis health report here for a deeper understanding of Proteomics International Laboratories.

• Assess Proteomics International Laboratories' future earnings estimates with our detailed growth reports.

Key Takeaways

• Dive into all 1,031 of the ASX Penny Stocks we have identified here.

• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Jump on the AI train with fast growing tech companies forging a new era of innovation.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:DOC ASX:LDR and ASX:PIQ.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com